FreshPatents.com Logo

new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)


Similar
Filing Names

Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals Inc_20100128
Regeneron Pharmaceuticals Inc_20131212

Popular
Companies


Web
Adobe patents
Akamai patents
Amazon patents
Apple patents
Ebay patents
Facebook patents
Google patents
IBM patents
Linkedin patents
Microsoft patents
Oracle patents
Red Hat patents
Yahoo patents

Food/Health
Adidas
Nike patents
Pfizer patents
Monsanto patents
Medtronic patents
Kraft patents

Transportation
Boeing patents
Tesla Motors patents

Telecom
Qualcomm patents
Motorola patents
Nokia patents
RIMM patents

Industrial/Electronics
AMD
Applied Materials
Seagate patents
General Electric
Caterpillar patents
Samsung
Wal-mart patents

Ticker Symbols

Regeneron Pharmaceuticals, Inc. patents


      
Recent patent applications related to Regeneron Pharmaceuticals, Inc.. Regeneron Pharmaceuticals, Inc. is listed as an Agent/Assignee. Note: Regeneron Pharmaceuticals, Inc. may have other listings under different names/spellings. We're not affiliated with Regeneron Pharmaceuticals, Inc., we're just tracking patents.

ARCHIVE: New 2014 2013 2012 2011 2010 2009 | Company Directory "R" | Regeneron Pharmaceuticals, Inc.-related inventors



Search recent Press Releases: Regeneron Pharmaceuticals, Inc.-related press releases
Count Application # Date Regeneron Pharmaceuticals, Inc. patents (updated weekly) - BOOKMARK this page
12014025539009/11/14 new patent  Method of treating rheumatoid arthritis with an anti-il-6r antibody
22014025541909/11/14 new patent  Method of treating stress hyperglycemia with human antibodies to the glucagon receptor
32014025542909/11/14 new patent  Methods of treating autoimmune diseases with dll4 antagonists
42014025599509/11/14 new patent  High affinity antibodies to human il-6 receptor
52014024866409/04/14Readily isolated bispecific antibodies with native immunoglobulin format
62014024350408/28/14Antibodies comprising chimeric constant domains
72014024546608/28/14Humanized t cell co-receptor mice
82014024546708/28/14Genetically modified major histocompatibility complex mice
92014024546808/28/14Non-human animals with modified immunoglobulin heavy chain sequences
102014022002308/07/14Method of treating osteoarthritis with an antibody to ngf
112014021377307/31/14Adam6 mice
122014019655007/17/14Systems and devices for sample handling
132014019976107/17/14Promoter-regulated differentiation-dependent self-deleting cassette
142014019340207/10/14Anti-pdgfr-beta antibodies and uses thereof
152014019459707/10/14Modified chimeric polypeptides with improved pharmacokinetic properties
162014018990007/03/14Mirna-regulated differentiation-dependent self-deleting cassette
172014017887906/26/14Compositions and methods for modifying cells
182014017990306/26/14High affinity human antibodies to human protease-activated receptor 2
192014015470106/05/14Humanized fc gamma r mice
202014015568906/05/14Methods of modifying genes in eukaryotic cells
212014015744506/05/14Low affinity fcgr deficient mice
222014013797805/22/14System and methods for use in dispensing biopharmaceutical materials
232014013797805/22/14System and methods for use in dispensing biopharmaceutical materials
242014013416905/15/14Methods of treating ovarian cancer with dll4 antagonists
252014013418905/15/14Anti-prokineticin receptor (prokr) antibodies and uses thereof
262014013471905/15/14Recombinant cell surface capture proteins
272014013727505/15/14Hybrid light chain mice
282014013416905/15/14Methods of treating ovarian cancer with dll4 antagonists
292014013418905/15/14Anti-prokineticin receptor (prokr) antibodies and uses thereof
302014013471905/15/14Recombinant cell surface capture proteins
312014013727505/15/14Hybrid light chain mice
322014013019305/08/14Mice that make vl binding proteins
332014013019405/08/14Mice that make vl binding proteins
342014013019305/08/14Mice that make vl binding proteins
352014013019405/08/14Mice that make vl binding proteins
362014012010905/01/14Human antibodies to human tnf-like ligand 1a (tl1a)
372014012010905/01/14Human antibodies to human tnf-like ligand 1a (tl1a)
382014011293004/24/14Methods for treating or preventing malaria by administering an antibody that specifically binds angiopoietin-2 (ang-2)
392014011293004/24/14Methods for treating or preventing malaria by administering an antibody that specifically binds angiopoietin-2 (ang-2)
402014009931204/10/14Methods for treating hypercholesterolemia and reducing ldl-c using antibodies to pcsk9
412014009931204/10/14Methods for treating hypercholesterolemia and reducing ldl-c using antibodies to pcsk9
422014009931204/10/14Methods for treating hypercholesterolemia and reducing ldl-c using antibodies to pcsk9
432014008829503/27/14Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof
442014008829503/27/14Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof
452014008276003/20/14Non-human animals expressing ph-sensitive immunoglobulin sequences
462014008276003/20/14Non-human animals expressing ph-sensitive immunoglobulin sequences
472014007256303/13/14Methods and compositions comprising a combination of an anti-erbb3 antibody and an anti-egfr antibody
482014007258303/13/14Methods for treating atopic dermatitis by administering an il-4r antagonist
492014007297903/13/14Isolating cells expressing secreted proteins
502014007298003/13/14Isolating cells expressing secreted proteins
512014007301003/13/14Methods of modifying eukaryotic cells
522014007558603/13/14Parental cell lines for making cassette-free f1 progeny
532014007256303/13/14Methods and compositions comprising a combination of an anti-erbb3 antibody and an anti-egfr antibody
542014007258303/13/14Methods for treating atopic dermatitis by administering an il-4r antagonist
552014007297903/13/14Isolating cells expressing secreted proteins
562014007298003/13/14Isolating cells expressing secreted proteins
572014007301003/13/14Methods of modifying eukaryotic cells
582014007558603/13/14Parental cell lines for making cassette-free f1 progeny
592014005690302/27/14Human antibodies to gfr alpha 3 and methods of use thereof
602014005690702/27/14Anti-asic1 antibodies and uses thereof
612014004473002/13/14Anti-pcsk9 antibodies with ph-dependent binding characteristics
622014004106802/06/14Methods of modifying eukaryotic cells
632014003333601/30/14Methods of modifying eukaryotic cells
642014003333701/30/14Methods of modifying eukaryotic cells
652014002363701/23/14Methods of modifying eukaryotic cells
662014001722801/16/14Humanized light chain mice
672014001722901/16/14Methods of modifying eukaryotic cells
682014001723801/16/14Methods of modifying eukaryotic cells
692014001769501/16/14Isolating cells expressing secreted proteins
702014001778101/16/14Methods of modifying eukaryotic cells
712014001778201/16/14Methods for modifying eukaryotic cells
722014001852201/16/14Methods of modifying eukaryotic cells
732014002012401/16/14Methods of modifying eukaryotic cells
742014002012501/16/14Methods of modifying eukaryotic cells
752014001345601/09/14Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
762014001345701/09/14Methods of modifying eukaryotic cells
772013034453812/26/13Human antibodies to the glucagon receptor
782013034010412/19/13Humanized il-7 rodents
792013033305712/12/13Humanized non-human animals with restricted immunoglobulin heavy chain loci
802013033305712/12/13Humanized non-human animals with restricted immunoglobulin heavy chain loci
812013032326012/05/13Stabilized formulations containing anti-dll4 antibodies
822013032326112/05/13Purified antibody composition
832013032378812/05/13Production cell line enhancers
842013032379012/05/13Human lambda light chain mice
852013032379112/05/13Restricted immunoglobulin heavy chain mice
862013032664712/05/13Human lambda light chain mice
872013030967011/21/13Nuclease-mediated targeting with large targeting vectors
882013031212811/21/13Promoter-regulated differentiation-dependent self-deleting cassette
892013031212911/21/13Promoter-regulated differentiation-dependent self-deleting cassette
902013029509711/07/13Human antibodies to fel d1 and methods of use thereof
912013028075810/24/13Fusion polypeptides capable of activating receptors
922013027307010/17/13Methods for treating or preventing influenza virus infection by administering a serine protease inhibitor
932013026657410/10/13Human antibodies to human angiopoietin-like protein 4
942013025987610/03/13Anti-hla-b*27 antibodies and uses thereof
952013025988110/03/13Fusion polypeptides capable of activating receptors
962013026105610/03/13Vegf antagonist formulations
972013025172809/26/13Method of treating stress hyperglycemia with human antibodies to the glucagon receptor
982013025491109/26/13Adam6 mice
992013024377509/19/13Multispecific antigen-binding molecules and uses thereof
1002013024378409/19/13Methods for reducing lipoprotein(a) levels by administering an inhibitor of proprotein convertase subtilisin kexin-9 (pcsk9)
1012013024723409/19/13Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
1022013024723509/19/13Mice that produce antigen-binding proteins with ph-dependent binding characteristics
1032013024723609/19/13Non-human animals expressing ph-sensitive immunoglobulin sequences
1042013023053109/05/13Human antibodies to clostridium difficile toxins
1052013023053309/05/13Methods of treating systemic lupus erythematosus (sle) using anti-cd48 antibodies
1062013021654708/22/13Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
1072013021654708/22/13Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
1082013020949208/15/13Anti-tie2 antibodies and uses thereof
1092013021013708/15/13Methods of modifying eukaryotic cells
1102013021271908/15/13Humanized rodents that express heavy chain containing vl domains
1112013020949208/15/13Anti-tie2 antibodies and uses thereof
1122013021013708/15/13Methods of modifying eukaryotic cells
1132013021271908/15/13Humanized rodents that express heavy chain containing vl domains
1142013019587808/01/13Anti-asic1 antibodies and uses thereof
1152013019887908/01/13Humanized universal light chain mice
1162013019888008/01/13Mice expressing a limited immunoglobulin light chain repertoire
1172013019587808/01/13Anti-asic1 antibodies and uses thereof
1182013019887908/01/13Humanized universal light chain mice
1192013019888008/01/13Mice expressing a limited immunoglobulin light chain repertoire
1202013018679707/25/13Stabilized formulations containing anti-ang2 antibodies
1212013018927707/25/13Stabilized formulations containing anti-pcsk9 antibodies
1222013018679707/25/13Stabilized formulations containing anti-ang2 antibodies
1232013018927707/25/13Stabilized formulations containing anti-pcsk9 antibodies
1242013018420507/18/13Antitumor combinations containing a vegf-inhibiting agent and 5fu or a derivative thereof
1252013018581907/18/13Genetically modified major histocompatibility complex animals
1262013018582007/18/13Genetically modified major histocompatibility complex animals
1272013018582107/18/13Common light chain mouse
1282013018420507/18/13Antitumor combinations containing a vegf-inhibiting agent and 5fu or a derivative thereof
1292013018581907/18/13Genetically modified major histocompatibility complex animals
1302013018582007/18/13Genetically modified major histocompatibility complex animals
1312013018582107/18/13Common light chain mouse
1322013017114907/04/13Anti-angptl3 antibodies and uses thereof
1332013017114907/04/13Anti-angptl3 antibodies and uses thereof
1342013016478606/27/13Fucosylation-deficient cells
1352013016478606/27/13Fucosylation-deficient cells
1362013015731306/20/13High affinity antibodies to human il-6 receptor
1372013016015306/20/13Humanized light chain mice
1382013015731306/20/13High affinity antibodies to human il-6 receptor
1392013016015306/20/13Humanized light chain mice
1402013014974406/13/13Methods for producing a fusion protein capable of binding vegf
1412013014974406/13/13Methods for producing a fusion protein capable of binding vegf
1422013013710105/30/13Methods of modifying eukaryotic cells
1432013013710105/30/13Methods of modifying eukaryotic cells
1442013012972205/23/13Methods for treating cancer by administering an anti-ang-2 antibody
1452013012983005/23/13Polymer protein microparticles
1462013013037205/23/13Enhanced expression and stability regions
1472013013038805/23/13Methods of modifying eurakyotic cells
1482013012972205/23/13Methods for treating cancer by administering an anti-ang-2 antibody
1492013012983005/23/13Polymer protein microparticles
1502013013037205/23/13Enhanced expression and stability regions
1512013013038805/23/13Methods of modifying eurakyotic cells
1522013012200305/16/13Methods of inhibiting tumor growth by antagonizing il-6 receptor
1532013012200705/16/13Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing gdf8 and or activin a
1542013012200305/16/13Methods of inhibiting tumor growth by antagonizing il-6 receptor
1552013012200705/16/13Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing gdf8 and or activin a
1562013011787305/09/13Humanized il-6 and il-6 receptor
1572013011787305/09/13Humanized il-6 and il-6 receptor
1582013010905305/02/13Genetically modified t cell receptor mice
1592013011161605/02/13Genetically modified major histocompatibility complex mice
1602013011161705/02/13Genetically modified major histocompatibility complex mice
1612013009556504/18/13Mirna-regulated differentiation-dependent self-deleting cassette
1622013009628704/18/13Restricted immunoglobulin heavy chain mice
1632013008429704/04/13Anti-erbb3 antibodies and uses thereof
1642013008463504/04/13Cell culture compositions capable of producing a vegf-binding fusion polypeptide
1652013008526604/04/13Anti-pcsk9 antibodies with ph-dependent binding characteristics
1662013007867503/28/13High affinity human antibodies to human il-4 receptor
1672013006483403/14/13Methods for treating hypercholesterolemia using antibodies to pcsk9
1682013004549202/21/13Methods for making fully human bispecific antibodies using a common light chain
1692013003490202/07/13Fusion polypeptides capable of activating receptors
1702013002889201/31/13Method of treating osteoarthritis with an antibody to ngf
1712012032210812/20/12Adam6 mice
1722012032349712/20/12Non-hypergeometric overlap probability
1732012025809810/11/12Method of treating rheumatoid arthritis with an anti-il-6r antibody
1742012026035710/11/12Low affinity fcgr deficient mice
1752012019589608/02/12Igf-1 fusion polypeptides and therapeutic uses thereof
1762012018963507/26/12Methods for treating or preventing malaria by administering an antibody that specifically binds angiopoietin-2 (ang-2)
1772012019230007/26/12Common light chain mouse
1782012017868307/12/12Vegf antagonist formulations
1792012016468806/28/12High affinity human antibodies to human nerve growth factor
1802012013501005/31/12High affinity human antibodies to human il-4 receptor
1812012012867905/24/12Human antibodies to the glucagon receptor
1822012011464505/10/12Use of il-1 antagonists to treat pseudogout
1832012011465405/10/12Human antibodies to human tnf-like ligand 1a (tl1a)
1842012011466505/10/12Human antibodies to human rankl
1852012009756504/26/12Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
1862012010014504/26/12Methods for treating b-cell lymphoma by administering an anti-cd20 antibody
1872012010103504/26/12Vegf antagonist formulations
1882012009382404/19/12Methods for treating pruritus by administering an antibody that specifically binds human par2
1892012009657204/19/12Mice that make vl binding proteins
1902012008792904/12/12Vegf antagonist formulations for intravitreal administration
1912012008300004/05/12Neuropeptide release assay for sodium channels
1922012007679003/29/12Anti-cd48 antibodies and uses thereof
1932012007086103/22/12Human lambda light chain mice
1942012007300403/22/12Hybrid light chain mice
1952012006462103/15/12Cell culture compositions capable of producing a vegf-binding fusion polypeptide
1962012005207203/01/12High affinity human antibodies to human il-4 receptor
1972012004544002/23/12Method of treating rheumatoid arthritis with an anti-il-6r antibody
1982012002140901/26/12Common light chain mouse
1992012001496801/19/12Stabilized formulations containing anti-ngf antibodies
2002012000369701/05/12High affinity antibodies to human il-6 receptor
2012011031834212/29/11Methods of using il-1 antagonists to treat autoinflammatory disease
2022011031153712/22/11Methods of using il-1 antagonists to treat familial mediterranean fever (fmf)
2032011030796612/15/11Mice expressing human voltage-gated sodium channels
2042011030796812/15/11Production of fertile xy animals from xy es cells
2052011029363012/01/11Antibodies to human gdf8
2062011028337611/17/11Methods of modifying eukaryotic cells
2072011026918711/03/11High affinity human antibodies to human il-18 receptor
2082011025614810/20/11Methods for treating hypercholesterolemia using antibodies to pcsk9
2092011025655610/20/11Humanized fcgr mice
2102011025658710/20/11High affinity human antibodies to human nerve growth factor
2112011025760110/20/11Vegf antagonist formulations for intravitreal administration
2122011025871010/20/11Methods of modifying eukaryotic cells
2132011019545408/11/11Common light chain mouse
2142011018917608/04/11Methods of treating diseases with dll4 antagonists
2152011018920008/04/11Methods of treating autoimmune diseases with dll4 antagonists
2162011017124107/14/11Stabilized formulations containing anti-interleukin-6 (il-6) antibodies
2172011016565007/07/11Fusion polypeptides capable of activating receptors
2182011015901506/30/11Human antibodies to human angiopoietin-like protein 4
2192011015090506/23/11Human antibodies to human delta like ligand 4
2202011015451206/23/11Humanized fc gamma r mice
2212011014593706/16/11Mice that make heavy chain antibodies
2222011010479905/05/11Multifunctional alleles
2232011008168104/07/11Human antibodies to human cd20 and method of using thereof
2242011006590203/17/11High affinity human antibodies to pcsk9
2252011005909503/10/11High affinity human antibodies to human protease-activated receptor-2
2262011004119602/17/11Mirna-regulated differentiation-dependent self-deleting cassette
2272011004119702/17/11Promoter-regulated differentiation-dependent self-deleting cassette
2282011002728602/03/11High affinity human antibodies to human angiopoietin-2
2292011002034201/27/11Igf-1 fusion polypeptides and therapeutic uses thereof
2302011001420801/20/11Method of treating osteoarthritis with an antibody to ngf
2312011000837401/13/11Use of il-1 antagonists to treat gout
2322010033010612/30/10Method of treating cancer with dll4 antagonist and chemotherapeutic agent
2332010033152712/30/10Readily isolated bispecific antibodies with native immunoglobulin format
2342010031662712/16/10Human antibodies to human il-6 receptor
2352010031663612/16/10Method of treating rheumatoid arthritis with an il-6r antibody
2362010030443612/02/10Fucosylation-deficient cells
2372010029110711/18/10High affinity human antibodies to human il-4 receptor
2382010029162611/18/10Enhanced expression and stability regions
2392010027993311/04/10Vegf antagonist formulations
2402010023380309/16/10Fusion polypeptides capable of activating receptors
2412010022178209/02/10Modified chimeric polypeptides with improved pharmacokinetic properties
2422010016676807/01/10High affinity human antibodies to pcsk9
2432010012981705/27/10Identifying germline competent embryonic stem cells
2442010011192105/06/10Use of il-1 antagonists to treat gout
2452010008763204/08/10Vegf-binding fusion proteins and therapeutic uses thereof
2462010007590303/25/10Lyophilized vegf antagonist formulations for intravitreal administration
2472010004725402/25/10High affinity human antibodies to human il-4 receptor
2482010004233002/18/10Non-hypergeometric overlap probability
2492010003483302/11/10High affinity human antibodies to human il-18 receptor


ARCHIVE: New 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Regeneron Pharmaceuticals, Inc. in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Regeneron Pharmaceuticals, Inc. with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###

     SHARE
  
         


FreshNews promo